1 – 15 of 15
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Acoustic Enrichment of Heterogeneous Circulating Tumor Cells and Clusters from Metastatic Prostate Cancer Patients
(
- Contribution to journal › Article
-
Mark
Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial
2024) In European Urology(
- Contribution to journal › Article
-
Mark
Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer : Big Data Analytics Using the PIONEER Platform
(
- Contribution to journal › Article
- 2023
-
Mark
Acoustophoresis enrichment of tumor cell clusters in blood of patients with metastatic prostate cancer
2023) The 27th International Conference on Miniaturized Systems for Chemistry and Life Sciences (µTAS 2023)(
- Contribution to conference › Abstract
-
Mark
Acoustic enrichment of heterogenous circulating tumor cells and clusters from patients with metastatic prostate cancer
2023)(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
Acoustophoresis enriches tumor cell clusters in blood of patients with prostate cancer
2023) Acoustofluidics Conference 2023, St. Louis USA(
- Contribution to conference › Abstract
-
Mark
Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)
(
- Contribution to journal › Article
- 2022
-
Mark
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
(
- Contribution to journal › Article
- 2021
-
Mark
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19) : a structured summary of a study protocol for a randomised controlled trial
(
- Contribution to journal › Letter
- 2017
-
Mark
Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer
(
- Contribution to journal › Article
- 2016
-
Mark
Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.
(
- Contribution to journal › Article
- 2015
-
Mark
Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer
2015) American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium In Journal of Clinical Oncology 33(15 Suppl). p.5044-5044(
- Contribution to journal › Published meeting abstract
- 2014
-
Mark
High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
(
- Contribution to journal › Article
- 2013
-
Mark
The Study of Active Monitoring in Sweden (SAMS): A randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer.
(
- Contribution to journal › Scientific review
- 2011
-
Mark
LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer
(
- Contribution to journal › Article